[Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
D000978:Antiparkinson Agents; D004359:Drug Therapy, Combination; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D007980:Levodopa / Q000008:administration & dosage; D008995:Monoamine Oxidase / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D007527:Isoenzymes; D010627:Phenethylamines; D012642:Selegiline; D007980:Levodopa; D008995:Monoamine Oxidase
Le basi biochimiche dell'uso degli inibitori selettivi delle monoaminossidasi nella terapia del morbo di Parkinson. Contributo critico.